Biotransport carriers could assist in discovery of new therapies from the human genome.Supratek Pharma, Inc (Montreal Montreal (mŏn'trēôl`), Fr. Montréal (môNrāäl`), city (1991 pop. 1,017,666), S Que., Canada, on Montreal island, surrounded by St. Lawrence River and Rivière des Prairies. , Canada; 514-849-6094) announced the publication of an important paper by its scientists in the prestigious scientific journal Gene Therapy. Oleg Romar, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. stated that, "It is especially satisfying to make this announcement at the same time as the first draft of the Human Genome The human genome is the genome of Homo sapiens, which is composed of 24 distinct pairs of chromosomes (22 autosomal + X + Y) with a total of approximately 3 billion DNA base pairs containing an estimated 20,000–25,000 genes. is published. As we have heard, this milestone is expected to herald the start of a new age in gene-based medicines and therapies. We believe that Supratek's SP1017-T Biotransport technology will have a significant role to play in successfully translating genomics information to effective gene-based medicines and therapies. In this publication, we show how, in a gene therapy program, our non-viral delivery system, SP1017-T, is able to achieve levels of therapeutic gene expression that are comparable to viral-based delivery systems. This is extremely important from a safety and efficacy point of view. In earlier work, we were able to show how the SP1017-Vac carrier was able to significantly enhance the efficiency of DNA vaccination DNA vaccination is a proposed experimental technique for protecting an organism against disease by injecting it with naked DNA to produce an immunological response. Thus far, few experimental trials have evoked a response sufficiently strong enough to protect against disease, and . Combined, these results show that an important set of new tools have been created for safe, efficient and effective delivery of DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. vaccines and therapeutic proteins for gene therapy." Supratek has developed a set of drug delivery technologies, called Biotransport which increases drug availability and safety. Most importantly Adv. 1. most importantly - above and beyond all other consideration; "above all, you must be independent" above all, most especially , Biotransport improves biological response to drugs thereby increasing efficacy and reducing side effects Side effects Effects of a proposed project on other parts of the firm. . SP1017-T is one of Supratek's novel Biotransport carriers that enhance the efficiency of gene expression used in gene therapy. An extensive composition and use patent estate filed in all of the key markets protects Biotransport technology, including SP1017-T and SP1017-Vac. Consequently, incorporation of a drug in Supratek's Biotransport carrier systems results in a new product protected by patent. Supratek Pharma is a pharmaceutical research company founded in 1994. Supratek is dedicated to fighting major human diseases by "making discovered drugs better and discovering better drugs". Supratek's Biotransport carrier technology combines drug delivery and biological response modification to provide drugs with novel mechanisms of action and improved biological activity, without modification of the parent compound. Supratek has ten products in its pipeline. Seven are anti-cancer products, including one in late Phase I clinical trials Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I . |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion